ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NeuroSense Reports Positive Results in ALS Study, Patent Allowance for PrimeC
March 08, 2021NeuroSense Therapeutics has announced the successful completion of its first Phase IIa study. The study, NST002, aimed at establishing various safety endpoints for the company's first drug candidate PrimeC in 15 ALS patients, over a 12-month period. -
NeuroSense Announces Continuation of Positive Trends in ALS Clinical Study
December 04, 2020NeuroSense Therapeutics continues to report promising trends in their NST002 Phase IIa study, conducted in Israel at Tel-Aviv Sourasky Medical Center (TASMC).
Pharma Sources Insight January 2025
